Diagnostic Phase

Summary:

One of the important problems in cancer treatment is its diagnosis in the early stages and evaluation of response to treatment. Therefore, using the appropriate diagnostic methods with high efficiency and proper biomarkers for diagnosis and treatment of cancer patients is necessary. The present study aims to evaluate the expression level alterations of miRNAs 21, 155, 10b and Let-7a, and also the blood plasma-derived Matrix metalloproteinases 1, 2, 9, 11 and 13 in breast cancer patients. Inclusion criteria are included 30 breast cancer patients who will refer to Cancer Institute of Imam Khomeini hospital from October 2016 until October 2017. After inclusion, 5 ml whole blood will be collected from all the patients in both stages of diagnosis and after the treatment (after surgery and chemotherapy). After centrifugation, all samples will be maintained at -80 °C until the assessment time. Then, RNA extraction from blood and tissue, cDNA synthesis and quantitative analyses for the expressions of miRNAs 10b, 155, 21 and Let-7a, and also Matrix metalloproteinases 1, 2, 9, 11 and 13 will be performed by gelatin quantitative zymography.